141 related articles for article (PubMed ID: 38191615)
21. Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical Trial.
Lehmann BD; Abramson VG; Dees EC; Shah PD; Ballinger TJ; Isaacs C; Santa-Maria CA; An H; Gonzalez-Ericsson PI; Sanders ME; Newsom KC; Abramson RG; Sheng Q; Hsu CY; Shyr Y; Wolff AC; Pietenpol JA
JAMA Oncol; 2024 Feb; 10(2):193-201. PubMed ID: 38095878
[TBL] [Abstract][Full Text] [Related]
22. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study.
Loibl S; Untch M; Burchardi N; Huober J; Sinn BV; Blohmer JU; Grischke EM; Furlanetto J; Tesch H; Hanusch C; Engels K; Rezai M; Jackisch C; Schmitt WD; von Minckwitz G; Thomalla J; Kümmel S; Rautenberg B; Fasching PA; Weber K; Rhiem K; Denkert C; Schneeweiss A
Ann Oncol; 2019 Aug; 30(8):1279-1288. PubMed ID: 31095287
[TBL] [Abstract][Full Text] [Related]
23. Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial.
Mai HQ; Chen QY; Chen D; Hu C; Yang K; Wen J; Li J; Shi Y; Jin F; Xu R; Pan J; Qu S; Li P; Hu C; Liu YC; Jiang Y; He X; Wang HM; Lim WT; Liao W; He X; Chen X; Wang S; Yuan X; Li Q; Lin X; Jing S; Chen Y; Lu Y; Hsieh CY; Yang MH; Yen CJ; Samol J; Luo X; Wang X; Tang X; Feng H; Yao S; Keegan P; Xu RH
JAMA; 2023 Nov; 330(20):1961-1970. PubMed ID: 38015220
[TBL] [Abstract][Full Text] [Related]
24. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.
Cortes J; Rugo HS; Cescon DW; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Perez-Garcia J; Iwata H; Masuda N; Torregroza Otero M; Gokmen E; Loi S; Guo Z; Zhou X; Karantza V; Pan W; Schmid P;
N Engl J Med; 2022 Jul; 387(3):217-226. PubMed ID: 35857659
[TBL] [Abstract][Full Text] [Related]
25. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.
Winer EP; Lipatov O; Im SA; Goncalves A; Muñoz-Couselo E; Lee KS; Schmid P; Tamura K; Testa L; Witzel I; Ohtani S; Turner N; Zambelli S; Harbeck N; Andre F; Dent R; Zhou X; Karantza V; Mejia J; Cortes J;
Lancet Oncol; 2021 Apr; 22(4):499-511. PubMed ID: 33676601
[TBL] [Abstract][Full Text] [Related]
26. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
Wang J; Lu S; Yu X; Hu Y; Sun Y; Wang Z; Zhao J; Yu Y; Hu C; Yang K; Feng G; Ying K; Zhuang W; Zhou J; Wu J; Leaw SJ; Zhang J; Lin X; Liang L; Yang N
JAMA Oncol; 2021 May; 7(5):709-717. PubMed ID: 33792623
[TBL] [Abstract][Full Text] [Related]
27. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
[TBL] [Abstract][Full Text] [Related]
28. FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1.
Narayan P; Wahby S; Gao JJ; Amiri-Kordestani L; Ibrahim A; Bloomquist E; Tang S; Xu Y; Liu J; Fu W; Song P; King-Kallimanis BL; Hou S; Gong Y; Kalavar S; Ghosh S; Philip R; Goldberg KB; Theoret MR; Blumenthal GM; Kluetz PG; Sridhara R; Pazdur R; Beaver JA
Clin Cancer Res; 2020 May; 26(10):2284-2289. PubMed ID: 32001481
[TBL] [Abstract][Full Text] [Related]
29. TORCHLIGHT trial, brightening the life of more patients with advanced triple-negative breast cancer.
Zhang H; Jin X; Bian L
Transl Breast Cancer Res; 2024; 5():1. PubMed ID: 38751675
[TBL] [Abstract][Full Text] [Related]
30. Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance).
Rugo HS; Barry WT; Moreno-Aspitia A; Lyss AP; Cirrincione C; Leung E; Mayer EL; Naughton M; Toppmeyer D; Carey LA; Perez EA; Hudis C; Winer EP
J Clin Oncol; 2015 Jul; 33(21):2361-9. PubMed ID: 26056183
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1-positive advanced cervical cancer: a phase II, single-arm study.
An J; Li X; Wang J; Zhu L; An R; Jiang K; Huang Y; Wang K; Li G; Wang C; Yuan J; Hou X; Yang G; Li J; Wang Q; Zhu J; Wu L
Front Immunol; 2023; 14():1142256. PubMed ID: 37153587
[TBL] [Abstract][Full Text] [Related]
32. Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer.
Hamilton E; Kimmick G; Hopkins J; Marcom PK; Rocha G; Welch R; Broadwater G; Blackwell K
Clin Breast Cancer; 2013 Dec; 13(6):416-20. PubMed ID: 24099649
[TBL] [Abstract][Full Text] [Related]
33. Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.
Schmid P; Abraham J; Chan S; Wheatley D; Brunt AM; Nemsadze G; Baird RD; Park YH; Hall PS; Perren T; Stein RC; Mangel L; Ferrero JM; Phillips M; Conibear J; Cortes J; Foxley A; de Bruin EC; McEwen R; Stetson D; Dougherty B; Sarker SJ; Prendergast A; McLaughlin-Callan M; Burgess M; Lawrence C; Cartwright H; Mousa K; Turner NC
J Clin Oncol; 2020 Feb; 38(5):423-433. PubMed ID: 31841354
[TBL] [Abstract][Full Text] [Related]
34. Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16).
Kim SH; Im SA; Suh KJ; Lee KH; Kim MH; Sohn J; Park YH; Kim JY; Jeong JH; Lee KE; Choi IS; Park KH; Kim HJ; Cho EK; Park SY; Kim M; Kim JH
Eur J Cancer; 2023 Dec; 195():113386. PubMed ID: 37890351
[TBL] [Abstract][Full Text] [Related]
35. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Kim SB; Dent R; Im SA; Espié M; Blau S; Tan AR; Isakoff SJ; Oliveira M; Saura C; Wongchenko MJ; Kapp AV; Chan WY; Singel SM; Maslyar DJ; Baselga J;
Lancet Oncol; 2017 Oct; 18(10):1360-1372. PubMed ID: 28800861
[TBL] [Abstract][Full Text] [Related]
36. Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE).
Kundranda M; Gracian AC; Zafar SF; Meiri E; Bendell J; Algül H; Rivera F; Ahn ER; Watkins D; Pelzer U; Charu V; Zalutskaya A; Kuesters G; Pipas JM; Santillana S; Askoxylakis V; Ko AH
Ann Oncol; 2020 Jan; 31(1):79-87. PubMed ID: 31912800
[TBL] [Abstract][Full Text] [Related]
37. Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.
Lam SW; de Groot SM; Honkoop AH; Jager A; ten Tije AJ; Bos MM; Linn SC; van den Bosch J; Kroep JR; Braun JJ; van Tinteren H; Boven E;
Eur J Cancer; 2014 Dec; 50(18):3077-88. PubMed ID: 25459393
[TBL] [Abstract][Full Text] [Related]
38. IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer.
Cortés J; André F; Gonçalves A; Kümmel S; Martín M; Schmid P; Schuetz F; Swain SM; Easton V; Pollex E; Deurloo R; Dent R
Future Oncol; 2019 Jun; 15(17):1951-1961. PubMed ID: 30977385
[TBL] [Abstract][Full Text] [Related]
39. Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.
Yu KD; Ye FG; He M; Fan L; Ma D; Mo M; Wu J; Liu GY; Di GH; Zeng XH; He PQ; Wu KJ; Hou YF; Wang J; Wang C; Zhuang ZG; Song CG; Lin XY; Toss A; Ricci F; Shen ZZ; Shao ZM
JAMA Oncol; 2020 Sep; 6(9):1390-1396. PubMed ID: 32789480
[TBL] [Abstract][Full Text] [Related]
40. Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study.
Vuylsteke P; Huizing M; Petrakova K; Roylance R; Laing R; Chan S; Abell F; Gendreau S; Rooney I; Apt D; Zhou J; Singel S; Fehrenbacher L
Ann Oncol; 2016 Nov; 27(11):2059-2066. PubMed ID: 27573562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
